Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $306.6 million.

  • Dexcom's Cash from Investing Activities rose 20095.49% to $306.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $536.0 million, marking a year-over-year increase of 35831.33%. This contributed to the annual value of $536.0 million for FY2025, which is 35831.33% up from last year.
  • As of Q4 2025, Dexcom's Cash from Investing Activities stood at $306.6 million, which was up 20095.49% from $192.8 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's Cash from Investing Activities ranged from a high of $414.9 million in Q4 2023 and a low of -$555.9 million during Q2 2023
  • In the last 5 years, Dexcom's Cash from Investing Activities had a median value of -$87.9 million in 2021 and averaged -$45.8 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 196708.33% in 2021, then skyrocketed by 69068.97% in 2022.
  • Over the past 5 years, Dexcom's Cash from Investing Activities (Quarter) stood at -$496.1 million in 2021, then surged by 60.87% to -$194.1 million in 2022, then soared by 313.76% to $414.9 million in 2023, then tumbled by 173.2% to -$303.7 million in 2024, then soared by 200.95% to $306.6 million in 2025.
  • Its Cash from Investing Activities stands at $306.6 million for Q4 2025, versus $192.8 million for Q3 2025 and -$63.6 million for Q2 2025.